

台灣神經內分泌腫瘤學會 2025 年度春季會
NET Symposium: Stable Precision in The Treatment of NET

日期：2025/04/19 (星期六) 14:00~18:00

主辦單位：台灣神經內分泌腫瘤學會(TNET)、台灣介入性膽胰內視鏡學會(TIPES)

協辦單位：台灣諾華股份有限公司、健喬信元醫藥生技股份有限公司

地點：集思台中新烏日會議中心

地址：烏日區高鐵東一路 26 號 3 樓 (高鐵台中站/台鐵新烏日站站內步行 5 分鐘)

Time	Topic		Speaker	Moderator
14:00~14:10	Opening Remarks		陳明晃 理事長 台灣神經內分泌腫瘤學會	
14:10~14:50	Rare NET, Insulinoma from Clinical Diagnosis to Medical Treatment		呂金盈 醫師 臺大醫院 代謝內分泌科	鄭祖耀 醫師 臺大醫院 檢驗醫學部
14:50~15:30	Clinical Features and Treatment of NET, ENETS 2025 Update		吳宜珍 醫師 高雄醫學大學 胃腸內科	顏家瑞 醫師 成大醫院 腫瘤醫學部
15:30~15:40	Coffee break			
15:40~16:20	Case Sharing	Evaluates the Use of RLT for NET	柯冠吟 醫師 臺大癌醫 核醫科	鄭媚方 醫師 臺大醫院 核醫科
16:20~17:00		Functional P- NET Refractory to Standard of SSA	楊陽生 醫師 臺中榮民總醫院 血液腫瘤科	白禮源 醫師 中國附醫 血液腫瘤
17:00~17:40		Advanced Neuroendocrine Tumors Option and Treatment	黃文冠 醫師 林口長庚醫院 腫瘤科	陳彥仰 醫師 高雄長庚 血液腫瘤科
17:40~18:00	Closing and QA		王秀伯 理事長 台灣介入性膽胰內視鏡學會	

學會教育積分：(申請中)

台灣外科醫學會	台灣內科醫學會
台灣消化系外科醫學會	台灣消化系醫學會
台灣內視鏡外科醫學會	台灣消化系內視鏡醫學會
中華民國醫用超音波醫學會	中華民國癌症醫學會
中華民國內分泌學會	中華民國核醫學會

Curriculum Vitae


Jin-Ying Lu March 16, 2025
TEL: 886-2-23123456 ext. 66245
E-mail: jinyinglu@ntuh.gov.tw; mdphdjyl@gmail.com

Current Appointments

2013– now Attending physician, Internal Medicine, National Taiwan University Hospital
2003– 2013 Attending physician, Laboratory Medicine, National Taiwan University Hospital

Business Address

R408, Dormitory for Medical Staff, National Taiwan University Hospital, No.1, Chang-Teh Street, Taipei 100, Taiwan

Education

2003 – 2011 Doctoral degree (**M.D., Ph.D.**), Institute of Clinical Medicine, College of Medicine, National Taiwan University
2006 – 2008 Post-doctoral research fellow, Johns Hopkins University School of Medicine, Baltimore, Maryland
1989 – 1996 Doctor of Medicine (**M.D.**), National Taiwan University, Taipei, Taiwan

Awards and Honors

2005 The Phi Tau Phi Scholastic Honor Member (1st)
2010 The Phi Tau Phi Scholastic Honor Member (2nd)
2011 The Phi Tau Phi Scholastic Honor Member (3rd)

Publications (1-35)

1. Lin YB, Hu HW, Chung AK, Lu JY, Wu WC, Chiu IH, Chu I, Lin CC, Lee JH, Nien FJ, Chen KY, Wu MH, Chen CN, Wang CW, Kuo TC, Lin CH, Cheng MF, Chiu WY, Kuo SW, Hsieh WH, Wang CY, Yang WS, Chen PL, Shih SR. Genomic Differences in Thyroid Cancers From Primary Sites Versus Distant Metastases in Individual Patients: A Clinical Perspective and Preliminary Report. Head Neck 2025. DOI: 10.1002/hed.28100.
2. Lin KY, Kuo YT, Cheng MF, Chen PL, Wang HP, Cheng TY, Chang CH, Kao HF, Yang SH, Li HY, Lin CH, Chou YT, Chung AK, Wu WC, Lu JY, Wang CY, Hsieh WH, Wen CY, Yang WS, Shih SR. Traits of Patients With Pituitary Tumors in Multiple Endocrine Neoplasia Type 1 and Comparing Different Mutation Status. J Clin Endocrinol

- Metab 2023;108(12):e1532-e1541. DOI: 10.1210/clinem/dgad387.
3. Han CL, Lai CT, Reyes AJ, Yang HC, Lu JY, Shih SR, Chen KY, Hoofnagle AN, Yu SL, Bocik W, Hiltke T, Chiu HC, Wan CY, Rodriguez H, Zhang V, Chen YJ. Lessons learned: establishing a CLIA-equivalent laboratory for targeted mass spectrometry assays - navigating the transition from research to clinical practice. Clin Proteomics 2024;21(1):12. DOI: 10.1186/s12014-024-09455-y.
 4. Chu WK, Er LK, Chang CC, Lu JY, Wu WC, Tsai YC, Lin YH, Wu VC. Visceral adiposity as a predictor of new-onset diabetes in patients with primary aldosteronism: a cohort study. Ther Adv Chronic Dis 2024;15:20406223241301892. DOI: 10.1177/20406223241301892.
 5. Lu JY, Ou HY, Wu CZ, Yang CY, Jiang JY, Lu CH, Jiang YD, Chang TJ, Chang YC, Hsieh ML, Wu WC, Li HY, Du YF, Lin CH, Hung HC, Tien KJ, Yeh NC, Lee SY, Yu HI, Chuang LM. A randomized trial on the effect of transcutaneous electrical nerve stimulator on glycemic control in patients with type 2 diabetes. Sci Rep 2023;13(1):2662. DOI: 10.1038/s41598-023-29791-7.
 6. Lu JY, Chen KH, Shih SR, Wen FY, Wu WC, Chen TC, Hu FC. Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study. Endocr Pract 2023;29(2):89-96. DOI: 10.1016/j.eprac.2022.11.005.
 7. Wu WC, Peng KY, Lu JY, Chan CK, Wang CY, Tseng FY, Yang WS, Lin YH, Lin PC, Chen TC, Huang KH, Chueh JS, Wu VC. Cortisol-producing adenoma-related somatic mutations in unilateral primary aldosteronism with concurrent autonomous cortisol secretion: their prevalence and clinical characteristics. Eur J Endocrinol 2022;187(4):519-530. DOI: 10.1530/EJE-22-0286.
 8. Chang CF, Yang MH, Lee JH, Shih SR, Lin CH, Chen CP, Wu CE, Lu JY. The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan. Am J Cancer Res 2022;12(11):5342-5350. (<https://www.ncbi.nlm.nih.gov/pubmed/36504909>).
 9. Wu KI, Chen CY, Jou TS, Jimmy Juang JM, Lu JY, Wang JJ. Effect of 3-Hydroxy-3-Methyl-Glutaryl-Coenzyme A Reductase Inhibitors on the Meibomian Gland Morphology in Patients with Dyslipidemia. Am J Ophthalmol 2020;219:240-252. DOI: 10.1016/j.ajo.2020.06.029.
 10. Lin CH, Chen KH, Chen KY, Shih SR, Lu JY. Immune checkpoint inhibitor therapy-induced hypophysitis approximately a case series of Taiwanese patients. J Formos Med Assoc 2019;118(1 Pt 3):524-529. DOI: 10.1016/j.jfma.2018.07.014.
 11. Lu JY, Cheng WC, Chen KY, Lin CC, Chang CC, Kuo KT, Chen PL. Using Ion Torrent sequencing to study genetic mutation profiles of fatal thyroid cancers. J Formos Med Assoc 2018;117(6):488-496. DOI: 10.1016/j.jfma.2017.05.007.
 12. Lu JY, Hung PJ, Chen PL, Yen RF, Kuo KT, Yang TL, Wang CY, Chang TC, Huang TS, Chang CC. Follicular thyroid carcinoma with NRAS Q61K and GNAS R201H mutations that had a good (131)I treatment response. Endocrinol Diabetes Metab Case Rep 2016;2016:150067. DOI: 10.1530/EDM-15-0067.
 13. Chen PL, Shih SR, Wang PW, Lin YC, Chu CC, Lin JH, Chen SC, Chang CC, Huang TS, Tsai KS, Tseng FY, Wang CY, Lu JY, Chiu WY, Chang CC, Chen YH, Chen YT, Fann CS, Yang WS, Chang TC. Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study. Nat Commun 2015;6:7633. DOI: 10.1038/ncomms8633.
 14. Lu JY, Lin YY, Boeke JD, Zhu H. Using functional proteome microarrays to study protein lysine acetylation. Methods Mol Biol 2013;981:151-65. DOI:

- 10.1007/978-1-62703-305-3_12.
15. Lu KY, Tao SC, Yang TC, Ho YH, Lee CH, Lin CC, Juan HF, Huang HC, Yang CY, Chen MS, Lin YY, Lu JY, Zhu H, Chen CS. Profiling lipid-protein interactions using nonquenched fluorescent liposomal nanovesicles and proteome microarrays. *Mol Cell Proteomics* 2012;11(11):1177-90. DOI: 10.1074/mcp.M112.017426.
 16. Lu JY, Lin YY, Zhu H, Chuang LM, Boeke JD. Protein acetylation and aging. *Aging (Albany NY)* 2011;3(10):911-2. DOI: 10.18632/aging.100398.
 17. Lu JY, Lin YY, Sheu JC, Wu JT, Lee FJ, Chen Y, Lin MI, Chiang FT, Tai TY, Berger SL, Zhao Y, Tsai KS, Zhu H, Chuang LM, Boeke JD. Acetylation of yeast AMPK controls intrinsic aging independently of caloric restriction. *Cell* 2011;146(6):969-79. DOI: 10.1016/j.cell.2011.07.044.
 18. Lu JY. Plasticizer event in Taiwan. *J Formos Med Assoc* 2011;110(9):553-4. DOI: 10.1016/j.jfma.2011.07.002.
 19. Lin YY, Lu JY, Zhang J, Walter W, Dang W, Wan J, Tao SC, Qian J, Zhao Y, Boeke JD, Berger SL, Zhu H. Protein acetylation microarray reveals that NuA4 controls key metabolic target regulating gluconeogenesis. *Cell* 2009;136(6):1073-84. DOI: 10.1016/j.cell.2009.01.033.
 20. Lu JY, Lin YY, Qian J, Tao SC, Zhu J, Pickart C, Zhu H. Functional dissection of a HECT ubiquitin E3 ligase. *Mol Cell Proteomics* 2008;7(1):35-45. DOI: 10.1074/mcp.M700353-MCP200.
 21. Lu JY, Huang KC, Chang LC, Huang YS, Chi YC, Su TC, Chen CL, Yang WS. Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. *J Biomed Sci* 2008;15(5):565-76. DOI: 10.1007/s11373-008-9261-z.
 22. Lin YY, Qi Y, Lu JY, Pan X, Yuan DS, Zhao Y, Bader JS, Boeke JD. A comprehensive synthetic genetic interaction network governing yeast histone acetylation and deacetylation. *Genes Dev* 2008;22(15):2062-74. DOI: 10.1101/gad.1679508.
 23. Yang WS, Yang YC, Chen CL, Wu IL, Lu JY, Lu FH, Tai TY, Chang CJ. Adiponectin SNP276 is associated with obesity, the metabolic syndrome, and diabetes in the elderly. *Am J Clin Nutr* 2007;86(2):509-13. DOI: 10.1093/ajcn/86.2.509.
 24. Lu JY, Su TC, Liu YH, Hsu HJ, Chen CL, Yang WS. Lower plasma adiponectin is correlated to higher alanine aminotransferase independent of metabolic factors and hepatitis B virus carrier status. *Intern Med J* 2007;37(6):365-71. DOI: 10.1111/j.1445-5994.2007.01364.x.
 25. Chien TI, Lu JY, Kao JT, Lee TF, Ho SY, Chang CY, Liu CW, Lee CH, Yan SN, Yang JY, Lin PC, Wang MJ. Comparison of three automated urinalysis systems--Bayer Clinitek Atlas, Roche Urisys 2400 and Arkray Aution Max for testing urine chemistry and detection of bacteriuria. *Clin Chim Acta* 2007;377(1-2):98-102. DOI: 10.1016/j.cca.2006.08.033.
 26. Chien TI, Lu JY, Kao JT, Cheng YC, Lee YF. Evaluation and improvement strategy of analytical turnaround time in the stat laboratory. *J Formos Med Assoc* 2007;106(7):558-64. DOI: 10.1016/S0929-6646(07)60006-0.
 27. Lu JY, Chuang LM, Yang WS, Tai TY, Lai MY, Chen PJ, Kao JH, Lee CZ, Lee HS. Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. *Liver Int* 2005;25(4):752-9. DOI: 10.1111/j.1478-3231.2005.1007.x.
 28. Tai TY, Lu JY, Chen CL, Lai MY, Chen PJ, Kao JH, Lee CZ, Lee HS, Chuang LM, Jeng YM. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. *J Endocrinol*

- 2003;178(3):457-65. DOI: 10.1677/joe.0.1780457.
29. Lu JY, Kao JT, Chien TI, Lee TF, Tsai KS. Effects of air bubbles and tube transportation on blood oxygen tension in arterial blood gas analysis. J Formos Med Assoc 2003;102(4):246-9. (<https://www.ncbi.nlm.nih.gov/pubmed/12833188>).
 30. Chang CY, Lu JY, Chien TI, Kao JT, Lin MC, Shih PC, Yan SN. Interference caused by the contents of serum separator tubes in the Vitros CRP assay. Ann Clin Biochem 2003;40(Pt 3):249-51. DOI: 10.1258/000456303321610556.
 31. Lu JY, Huang TS, Wu MZ. Hypopituitarism and nesidioblastosis in an elderly patient with orbital lymphoma. J Formos Med Assoc 2002;101(1):68-72. (<https://www.ncbi.nlm.nih.gov/pubmed/11911041>).
 32. Lu JY, Chang CC, Chang YL. Adrenal lymphoma and Addison's disease: report of a case. J Formos Med Assoc 2002;101(12):854-8. (<https://www.ncbi.nlm.nih.gov/pubmed/12632819>).
 33. Lu JY, Yu CL, Wu MZ. Pellagra in an immunocompetent patient with cytomegalovirus colitis. Am J Gastroenterol 2001;96(3):932-4. DOI: 10.1111/j.1572-0241.2001.03659.x.
 34. Lu JY, Lin CW, Chang TC, Chen YC. Diagnostic pitfalls of fine-needle aspiration cytology and prognostic impact of chemotherapy in thyroid lymphoma. J Formos Med Assoc 2001;100(8):519-25. (<https://www.ncbi.nlm.nih.gov/pubmed/11678001>).
 35. Lu JY, Chang CC, Tsai HC, Lin KS, Tsang YM, Huang KM. Diabetic ketoacidosis and hypogonadotropic hypogonadism in association with transfusional hemochromatosis in a man with beta-thalassemia major. J Formos Med Assoc 2001;100(7):492-6. (<https://www.ncbi.nlm.nih.gov/pubmed/11579617>).

Non-SCI Publications

1. Tang SY, Peng SH, Lin CH, Lee JK, Chou SC, Lu JY. (2019) Uncommon Presentation of Combined Graves' Disease and Pulmonary Embolism in a 32-year-old Woman. J Intern Med Taiwan 2019; 30: 351-357. (corresponding author)
2. Lu JY, Wang CS, Peng HY, Lin SY, Lee CN, et al. (2017) Insulin Autoantibody-Related Hypoglycemic Coma in a Pregnant Woman with Type 1 Diabetes Mellitus. MOJ Clin Med Case Rep 6(2): 00151. (first and corresponding author)
3. Chang SH, Tsai YX, Chen TF, Wu WC, Chen PL, Lu JY. (2017) A 49-Year-Old Man with Combined Myasthenia Gravis, Autoimmune Thyroiditis and IgG4 Orbitopathy. Transl Biomed. Vol.8 No.4:140. (corresponding author)

吳宜珍 醫師



現職：

高雄醫學大學醫學院 副院長、教授
高雄醫學大學附設醫院消化系中心 主任 & 院長室
秘書
台灣消化系內視鏡醫學會理事
台灣神經內分泌瘤學會理事
台灣胃癌學會監事

學歷：

1994-2001 國立台灣大學 醫學系醫學士
2005-2008 高雄醫學大學 醫學研究所 博士

經歷：

2020-2023 高雄醫學大學附設醫院胃腸內科主任
2018-2019 高雄醫學大學附設醫院消化系內視鏡中心主任
2015-至今 高雄醫學大學附設醫院食道癌團隊召集人

柯冠吟 醫師

學歷

高雄醫學大學醫學系 學士 (2004-2011)

臺大臨床醫學研究所 博士 (2019-2024)

現職

臺大癌醫分院核子醫學部主治醫師

臺大醫學院放射線科臨床助理教授

經歷

耶魯大學醫學院正子中心訪問學者 (2024/8-2025/1)

臺大癌醫分院核子醫學部主任 (2021/6/1-2024/7/31)

臺大癌醫分院核子醫學部主治醫師 (2020/1 迄今)

臺大總院核子醫學部主治醫師 (2018-2019)

臺大雲林分院核子醫學部主治醫師 (2016-2018)

臺大總院核子醫學部住院醫師 (2012-2016)

楊陽生醫師

e-mail: ysyang003175@yahoo.com.tw Tel: 04-23592525-3181

地址: 407204 台中市西屯區臺灣大道四段 1650 號 台中榮民總醫院 血液腫瘤科

學歷： 中國醫藥大學 醫學系畢業

訓練經歷： 台中榮民總醫院內科部 住院醫師、總醫師

台中榮民總醫院內科部 血液腫瘤科主治醫師 (1997.9 ~ now)

現職： 台中榮民總醫院 血液腫瘤科 主治醫師**專科及次專科簡歷：**

內科醫學會 內科專科醫師、內科專科指導醫師

癌症醫學會 腫瘤內科專科醫師、腫瘤內科專科指導醫師 血液病學會 血液病專科醫師、血液病專科指導醫師

血液及骨髓移植學會 血液及骨髓移植專科醫師、血液及骨髓移植專科指導醫師
乳房醫學會 乳房專科醫師

專長及興趣領域：

1. 固態腫瘤

NET (Neuroendocrine tumor) 神經內分泌腫瘤

GIST (Gastrointestinal stromal tumor) 胃腸道基質瘤

Gastric, Pancreatic, Biliary tract cancers 胃、膽、胰癌

Melanoma & Immuno-Oncology 惡性黑色素瘤與免疫療法

Breast cancer 乳癌

2 血液病相關癌症

.

Multiple myeloma

多發性骨髓瘤

CML (Chronic myeloid leukemia)

慢性骨髓性白血病

CLL (Chronic lymphocytic leukemia)

慢性淋巴球性白血病

MPN (Myeloproliferative neoplasm) 骨髓增生性疾病

Lymphoma 惡性淋巴瘤

癌症相關院內職務：

台中榮民總醫院 癌症防治中心 副主任 台中榮民總醫院 癌症專科團隊成員：

乳癌團隊、胃癌團隊、胰臟/膽道癌團隊、皮膚癌團隊

Curriculum Vitae

Name: Wen-Kuan Huang (黃文冠)

Citizenship: Taiwan.

Office Address & Tel No.: 5, Fu-shin st., Kueishan, Taoyuan, Taiwan, 333, R.O.C, 886-3-3281200 ext. 8825; FAX: 886-3-3272236

Education: 1999-2006, MD, School of Medicine, Chung Shan Medical College, Taichung, R.O.C.
2014-2020, PhD, Karolinska Institutet, Department of oncology-pathology, Stockholm, Sweden.

Postgraduate Training:

1. Sep. 2007-Jul. 2010: Residents, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
2. Jul. 2010-Aug. 2012: Fellowship, Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.

Employment Record:

September 2012-now: Attending Physician, Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan

September 2021-now: Physician scientist, Department of Medical Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan

February 2023-now: Assistant professor, College of Medicine, Chang Gung University, Taoyuan, Taiwan

Board Certification:

1. Sep. 14, 2005. Physician board, No.:039891
2. Dec. 07, 2010. Internal Physician board, No.:8626
3. Nov. 2012. Medical Oncology board, NO.:101014

Professional affiliation:

Formosan Medical Association
The Society of Internal Medicine
Taiwan Oncology Society

Research of Interest: cancer metabolism, immune microenvironment, DNA damage repair

Grants

1. CMRPG3B0951 肝膿瘍及反覆化膿性膽道炎與膽道癌的關係及預後 2012/9/1~2013/8/31 (PI)
2. CMRPG3D0521 免疫組織化學染色(IHC)與 DNA 定序對於亞洲族群原發性及轉移性惡性黑色素瘤特定基因 BRAF V600E 突變的比較分析 2014/2/1~2015/1/31 (PI)
3. 103-2314-B-182A-087 - (國科會)探討染色體不穩定作為新標靶治療肢端型黑色素瘤的研究 20140801~20151031 (co-PI)
4. 104-2314-B-182 -009 - (國科會)熊去氧膽酸使用與大腸直腸癌發生的關係：全國性世代研究

20150801~20161031 (co-PI)

5.105-2314-B-182 -025 -MY2 (國科會)癌症病人罹患情感性疾患的發生率、危險因子與死亡風險-全國性研究 20160801~20180731(co-PI)

6.107-2314-B-182 -050 - (國科會)探討前列腺癌病人接受荷爾蒙治療的不良作用 20180801~20190731 (co-PI)

7.108-2314-B-182A-063 - (國科會)微小核糖核酸介導胃腸道基質瘤 imatinib 抗藥性經由調控粒線體代謝研究 2019/08/01~ 2020/07/31 (PI)

8.CMRPG3K172 (二年期) 胃腸道基質瘤 miR-483-3p 調控有氧磷酸化及 imatinib 藥物反應透過抑制琥珀酸脫氫酵素機轉研究 2020/10/1~2022/9/30 (PI)

9.108-2314-B-182A-057- (國科會) 探討雄性激素剝奪治療對於小鼠血管發炎及後續動脈斑塊形成的影響 20190801~ 20221231 (co-PI)

10. 109-2314-B-182 -035-(國科會) 氟尿酸-輔助化療對接受手術治療大腸直腸癌患者的心臟毒性：台灣全國性世代研究 20200801~ 20211031 (co-PI)

11. 111-2314-B-182 -016-(國科會) 糖尿病病人使用 pioglitazone 對日後罹患癌症的風險：從巢式病例對照研究到依時間改變暴露的世代研究 20220801~ 20230731(co-PI)

12.111-2314-B-182A-031- (國科會)胃癌微衛星不穩定狀態與腫瘤免疫微環境特徵分析 2022/08/01 ~2023/07/31 (PI)

13. CMRPG3M2101 TIGIT 抗體結合 PD-1 抗體在微衛星不穩定胃癌療效研究 2022/12/1-2023/11/30 (PI)

14. CMRPG3N0481(三年期) HIF1-alpha 與 circCSPF6/CPSF6 相互作用促進胰腺癌生長 2023/07/01-2026/6/30 (PI)

15. 113-2314-B-182 -028 - (國科會) 建立肝內膽道癌小鼠模型探索免疫微環境與免疫反應標誌物 (PI)

Publications

1.**Huang WK**, Tang YJ, Wu CE, Hou MM, Hsu HC, Su PJ, Chiang NJ, Chen SC, Yeh CN, Chen JS, Chen MH, Hsieh CH, Chou WC. Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer. *Oncologist*. 2024 Nov 20 (2023):4.8, ONCOLOGY|Q1|70/322 (21.7%)

2. Chen Y, Su Y, Cao X, Siavelis I, Leo IR, Zeng J, Tsagkozis P, Hesla AC, Papakonstantinou A, Liu X, **Huang WK**, Zhao B, Haglund C, Ehnman M, Johansson H, Lin Y, Lehtiö J, Zhang Y, Larsson O, Li X, de Flon FH. Molecular Profiling Defines Three Subtypes of Synovial Sarcoma. *Adv Sci (Weinh)*. 2024 Sep 10. IF (2023):14.3, NANOSCIENCE& NANOTECHNOLOGY |Q1|12/140 (8.5%)

3. **Huang WK**, Zhang Z, Chen J, Lin J, Wang Y, Yan X, Zhang W, Ning S, & You Q. Coordination engineering of FeCo dual single-atom nanozymes with photothermal-enhanced

- cascaded catalysis for efficient pancreatic cancer immunotherapy. *Chemical Engineering Journal*. 2024, Sep; 496, 154203. IF (2023):13.1, ENGINEERING, ENVIRONMENTAL|Q1|3/81 (3.7%)
4. Hung LJ, Huang CY, Tung KC, Chen JS, Huang WK, Hsu CC, Fang YF, Wang CL, Liu PC, Yeh KY, Chang PH, Chang JW, Lin YC, Huang SF, Chou WC. Comprehensive genomic profiling in multiple cancer types: A comparative analysis of the National Biobank Consortium of Taiwan and clinical practice cohorts. *J Formos Med Assoc*. 2024 Sep 6:S0929-6646(24)00405-4. IF (2023):2.6, MEDICINE, GENERAL & INTERNAL|Q1|70/325 (21.5%)
 5. Chen DY, Chang SH, Huang WK, Hsieh IC, See LC. The cold temperature associated with new-onset heart failure after incorporating dynamic status of multimorbidity: nationwide cohort, Taiwan 2012-2019. *Eur J Prev Cardiol*. 2024 Aug 23:zwae260. IF(2023):8.4, CARDIAC & CARDIOVASCULAR SYSTEMS|Q1|16/220 (7.2%)
 6. Huang WK, Hung YL, Tsai CY, Wu CE, Chou WC, Hsu JT, Yeh TS, Chen JS, Wang SY, Yeh CN. Efficacy of first-line combination therapies versus gemcitabine monotherapy for advanced pancreatic cancer: a systematic review and network meta-analysis. *Am J Cancer Res*. 2024 Jul 15;14(7):3523-3532. IF(2023):3.6, ONCOLOGY|Q2|106/322 (32.9%)
 7. Chen CP, Lin SF, Yeh CN, Huang WK, Pan YR, Hsiao YT, Lo CH, Wu CE. Synergistic effects of the combination of trametinib and alpelisib in anaplastic thyroid cancer with BRAF and PI3KCA co-mutations. *Heliyon*. 2024 Mar 30;10(7):e29055. IF(2023):3.4, MULTIDISCIPLINARY SCIENCES|Q1|28/134 (20.8%)
 8. Chang PH, Chen HY, Chang YS, Su PJ, Huang WK, Lin CF, Hsieh JC, Wu CT. Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy. *Cancers(Basel)*. 2024 Feb 23;16(5):894. IF(2023):4.5, ONCOLOGY|Q1|78/322 (24.2%)
 9. Yu JH, Li PR, Chen DY, Huang WK, See LC. Mortality after major bleeding in Asian atrial fibrillation patients receiving different direct oral anticoagulants: a nationwide, propensity score study. *Sci Rep*. 2024 Feb 27;14(1):4771. IF(2023):3.8, MULTIDISCIPLINARY SCIENCES|Q1|25/134 (18.6%)
 10. Chou TT, Hsu HC, Twu CW, Huang WK, Huang HM, Weng SH, Chen MC. Prevalence of Obstructive Sleep Apnea Using Home Sleep Test in Taiwan During the Coronavirus Disease Pandemic. *Nat Sci Sleep*. 2023 Dec 22;15:1107-1116. IF(2023):3.0, NEUROSCIENCES |Q2|140/310
 11. Pan YR, Lai JC, Huang WK, Peng PH, Jung SM, Lin SH, Chen CP, Wu CE, Hung TH, Yu AL, Wu KJ, Yeh CN. PLK1 and its substrate MISP facilitate intrahepatic cholangiocarcinoma progression by promoting lymphatic invasion and impairing E-cadherin adherens junctions. *Cancer Gene Ther*. 2024 Feb;31(2):322-333. IF(2023): 4.8, ONCOLOGY|Q1|70/322 (21.7%)
 12. Huang WK, Hsu HC, Yang TS, Lu CW, Pan YR, Wu CE, Chung WH, Hung SI, Yeh CN. Zinc supplementation decreased incidence of grade ≥ 2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial. *Eur J Cancer*. 2023 Dec;195:113286. IF(2023):7.6, ONCOLOGY|Q1|38/322 (11.8%)

13. **Huang WK**, Hsu HC, Yang TS, Lu CW, Pan YR, Wu CE, Chung WH, Hung SI, Yeh CN. Zinc supplementation decreased incidence of grade ≥ 2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial. *J Am Acad Dermatol*. 2024 Feb;90(2):368-369. IF(2023):12.8, DERMATOLOGY|Q1|1/94 (1%)
14. Chen DY, Lee CH, Tsai ML, Hsieh MJ, Chuang CK, Pang ST, Chen SW, Tseng CN, Chang SH, Chu PH, Hsieh IC, Wu VC, **Huang WK***. Cancer Therapy-Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy. *J Am Heart Assoc*. 2023 Oct 3;12(19):e030447. IF(2023): 5.0, CARDIAC&CARDIOVASCULAR SYSTEMS|Q1|39/220 (17.7%)
15. Yu JH, Hsieh SH, Chen CH, **Huang WK**. Comparison of the safety, effectiveness, and usability of swab robot vs. manual nasopharyngeal specimen collection. *Heliyon*. 2023 Oct 13;9(10):e20757. IF(2023):3.4, MULTIDISCIPLINARY SCIENCES|Q1|28/134 (20.8%)
16. Chen CP, Yeh CN, Pan YR, **Huang WK**, Hsiao YT, Lo CH, Wu CE. Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer. *Biomed Pharmacother*. 2023 Oct;166:115389. IF(2023): 6.9, PHARMACOLOGY & PHARMACY|Q1|15/354 (4.2%)
17. Chang JW, Huang CJ, **Huang WK**, Wang YC, Hsieh JJ, Chang YY, Huang YL, Wu CL, Wang YH, Chen SJ, Tan KT, Chen CP, Wu CE. Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma. *Clin Transl Immunology*. 2023 Aug 29;12(8):e1465. IF(2023):4.6, IMMUNOLOGY|Q2|56/181 (30.9%)
18. Pan YR, Wu CE, Jung SM, Huang SC, Lin SH, Chou WC, Chang YC, Chen MH, Hung TH, Yu AL, **Huang WK***, Yeh CN. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation. *Int J Biol Sci*. 2023 May 21;19(9):2772-2786. IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)
19. Tseng CN, Chen DY, Chang SH, Huang WK, Hsieh MJ, See LC. Ambient Temperature Effect on Acute Myocardial Infarction by Risk Factors: Daily Data From 2000 to 2017, Taiwan. *JACC Asia*. 2023 Mar 14;3(2):228-238.
20. Yeh CN, **Huang WK**, Lu CW, Chen CP, Lin SH, Pan YR, Wu CE. A Potential Association of Zinc Deficiency and Tyrosine Kinase Inhibitor-Induced Hand-Foot Skin Reaction. *Biol Trace Elem Res*. 2023 Dec;201(12):5540-5545.
21. **Huang WK**, Huang SC, Chen CM, Lin PH, Wu CE, Chuang CK, Yeh CN. Marked Response to Larotrectinib in Pelvic Spindle Cell Sarcoma With Concurrent TPM3-NTRK1 Fusion and CDK4/MDM2 Amplification: A Case Report. *JCO Precis Oncol*. 2023 Jan;7:e2200528. IF(2023): 5.3, ONCOLOGY|Q1|61/322 (18.9%)
22. Chen HK, Su PJ, Wang YL, Chang KC, Su YL, Chang PH, Kuan FC, Hsieh CH, Kuo YC, Sheng TW, Chang CF, Yu SM, **Huang WK**, Lin YC, Tsan DL, Yu KJ, Lin PH, Chen HY, Chang YH, Pang ST, Chuang CK, Lai EC. Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-

resistant prostate cancer. *Int J Cancer*. 2023 Mar 15;152(6):1191-1201. IF(2023): 5.7, ONCOLOGY|Q1|54/322 (16.7%)

23. Pan YR, Wu CE, Huang WK, Chen MH, Lan KH, Yeh CN. Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. *Front Immunol*. 2022 Oct 20;13:982196. IF(2023): 5.7, IMMUNOLOGY|Q1|38/181 (20.9%)

24. Lin LC, Huang WK, Yen CC, Yang CY, Sung MT, Wong NSM, Chua DTT, Lee SWM, Chen JS, Yeh CN. Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience. *Front Oncol*. 2022 Oct 13;12:1028118. IF(2023): 3.5, ONCOLOGY|Q2|107/322 (33.2%)

25. Lun R, Roy DC, Hao Y, Deka R, Huang WK, Navi BB, Siegal DM, Ramsay T, Fergusson D, Shorr R, Dowlathshahi D. Incidence of stroke in the first year after diagnosis of cancer-A systematic review and meta-analysis. *Front Neurol*. 2022 Sep 20;13:966190.

26. Huang WK, Ho WP, Hsu HC, Chang SH, Chen DY, Chou WC, Chang PH, Chen JS, Yang TS, See LC. Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer. *Front Cardiovasc Med*. 2022 Aug 3;9:880956. IF(2023): 2.8, CARDIAC&CARDIOVASCULAR SYSTEMS|Q2|79/220 (35%)

27. Huang WK, Wu CE, Wang SY, Chang CF, Chou WC, Chen JS, Yeh CN. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges. *Curr Treat Options Oncol*. 2022 Sep;23(9):1303-1319. IF(2023):3.8, ONCOLOGY|Q2|102/322 (31.6%)

27. Wu CE, Chen CP, Huang WK, Pan YR, Aptullahoglu E, Yeh CN, Lunec J. p53 as a biomarker and potential target in gastrointestinal stromal tumors. *Front Oncol*. 2022 Jul 29;12:872202. . IF(2023): 3.5, ONCOLOGY|Q2|107/322 (33.2%)

28. Chang PH, Lee CH, Wu TM, Yeh KY, Wang HM, Huang WK, Chan SC, Chou WC, Kuan FC, Kuo HC, Kuo YC, Hu CC, Hsieh JC. Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer. *Ther Adv Med Oncol*. 2022 Jul 15;14:17588359221110182. IF(2023): 4.3, ONCOLOGY|Q2|88/322 (27.3%)

29. Lin LC, Huang WK, Yen CC, Yang CY, Sung MT, Wong NS, Chua DTT, Lee SWM, Chen JS, Yeh CN. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience. *Front Oncol*. 2022 Jun 29;12:883399. IF(2023): 3.5, ONCOLOGY|Q2|107/322 (33.2%)

30. Chen DY, Liu JR, Tseng CN, Hsieh MJ, Chuang CK, Pang ST, Chen SW, Hsieh IC, Chu PH, Chen JS, Wen-Cheng Chang J, Huang WK*, See LC. Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies. *JACC CardioOncol*. 2022 Jun 21;4(2):223-234. IF(2023): 12.0, ONCOLOGY|Q1|22/322 (6.8%)

31. Wang C, Wan H, Zhang H, Yang B, Huang WK, Sun W. Characterization of Ligand-Receptor Pair in Bladder Cancer Develops a Validated Scoring Model for Prognosis and Treatment Response. *Front Cell Dev Biol*. 2022 Jun 17;10:915798. IF(2023):4.6, DEVELOPMENTAL BIOLOGY|Q1|5/39 (12.8%)

32. Chen Y, You S, Li J, Zhang Y, Kokaraki G, Epstein E, Carlson J, Huang WK*, Haglund F.

Follicular Helper T-Cell-Based Classification of Endometrial Cancer Promotes Precise Checkpoint Immunotherapy and Provides Prognostic Stratification. *Front Immunol.* 2022 Jan 7;12:788959. IF(2023): 5.7, IMMUNOLOGY|Q1|38/181 (20.9%)

33. Chen DY, Chen CC, Tseng CN, Chen SW, Chang SH, Huang WK, Wen MS, Hsieh MJ, Hsieh IC. Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study. *EClinicalMedicine.* 2021 Oct 8;41:101149. IF(2023): 9.6, MEDICINE, GENERAL & INTERNAL|Q1|12/325 (3.6%)

34. Jin X, Yan J, Chen C, Chen Y, Huang WK. Integrated Analysis of Copy Number Variation, Microsatellite Instability, and Tumor Mutation Burden Identifies an 11-Gene Signature Predicting Survival in Breast Cancer. *Front Cell Dev Biol.* 2021 Sep 28;9:721505. IF(2023):4.6, DEVELOPMENTAL BIOLOGY|Q1|5/39 (12.8%)

35. Huang WK, Shi H, Akçakaya P, Zeljic K, Gangaev A, Caramuta S, Yeh CN, Bränström R, Larsson C, Lui WO. Imatinib Regulates miR-483-3p and Mitochondrial Respiratory Complexes in Gastrointestinal Stromal Tumors. *Int J Mol Sci.* 2021 Sep 30;22(19):10600. IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)

36. Liu CH, Sung PS, Li YR, Huang WK, Lee TW, Huang CC, Lee TH, Chen TH, Wei YC. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study. *PLoS Med.* 2021 Jul 19;18(7):e1003707. IF(2023):10.5, MEDICINE, GENERAL & INTERNAL|Q1|10/325 (3%)

37. Huang WK, Hsu HC, Chang SH, Chou WC, Chang PH, Chiang SF, Chang JW, Chen JS, Yang TS, See LC. Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis. *Front Pharmacol.* 2021 Jun 29;12:693009. IF(2023): 4.4, PHARMACOLOGY & PHARMACY|Q1|65/354 (18.3%)

38. Wu CE, Huang WK, Chou WC, Hsieh CH, Chang JW, Lin CY, Yeh CN, Chen JS. Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy. *Cancers (Basel).* 2021 Jun 23;13(13):3139. IF(2023):4.5, ONCOLOGY|Q1|78/322 (24%)

39. Chen DY, Su PJ, See LC, Liu JR, Chuang CK, Pang ST, Tseng CN, Chen SW, Hsieh IC, Chu PH, Lin YC, Hsu CL, Chang JW, Lin MS, Pang JS, Hsieh MJ, Huang WK*. Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study. *Prostate.* 2021 Sep;81(12):902-912. IF(2023): 2.7 UROLOGY&NEPHROLOGY|Q2| 36/126 (28.5%)

40. Chang YR, Huang WK, Wang SY, Wu CE, Chen JS, Yeh CN. A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters. *Cancers (Basel).* 2021 May 25;13(11):2587. IF(2023):4.5, ONCOLOGY|Q1|78/322 (24%)

41. Huang WK, Chen Y, Su H, Chen TY, Gao J, Liu Y, Yeh CN, Li S. ARHGAP25 Inhibits

Pancreatic Adenocarcinoma Growth by Suppressing Glycolysis via AKT/mTOR Pathway. *Int J Biol Sci*. 2021 Apr 24;17(7):1808-1820. IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)

42. Chen DY, Tseng CN, Hsieh MJ, Lan WC, Chuang CK, Pang ST, Chen SW, Chen TH, Chang SH, Hsieh IC, Chu PH, Wen MS, Chen JS, Chang JW, See LC, Huang WK*. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism. *JAMA Netw Open*. 2021 Feb 1;4(2):e2036304. IF(2023): 10.5, MEDICINE, GENERAL & INTERNAL|Q1|10/325 (3%)

43. Pan YR, Wu CE, Chen MH, Huang WK, Shih HJ, Lan KL, Yeh CN. Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model. *Vaccines (Basel)*. 2020 Nov 24;8(4):703. IF(2023): 5.2, MEDICINE, RESEARCH & EXPERIMENTAL|Q1|39/189 (1.5%)

44. Wu CE, Yeh DW, Pan YR, Huang WK, Chen MH, Chang JW, Chen JS, Wang YC, Yeh CN. Chromosomal Instability May Not Be a Predictor for Immune Checkpoint Inhibitors from a Comprehensive Bioinformatics Analysis. *Life (Basel)*. 2020 Nov 8;10(11):276.

45. Huang WK, Yeh CN. The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma. *Biomolecules*. 2020 Sep 30;10(10):1396. IF(2023):4.8, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|67/313 (21.4%)

46. Huang WK, Liu CH, Pang ST, Liu JR, Chang JW, Liaw CC, Hsu CL, Lin YC, See LC. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan. *JAMA Netw Open*. 2020 Aug 3;3(8):e2015189. IF(2023):10.5, MEDICINE, GENERAL & INTERNAL|Q1|10/325 (3%)

47. Huang WK, Gao J, Chen Z, Shi H, Yuan J, Cui HL, Yeh CN, Bränström R, Larsson C, Li S, Lui WO. Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor. *Cells*. 2020 May 26;9(6):1333. IF(2023): 5.1, CELL BIOLOGY|Q2|63/205 (30.7%)

48. Huang WK, Chang SH, Hsu HC, Chou WC, Yang TS, Chen JS, Chang JW, Lin YC, Kuo CF, See LC. Postdiagnostic metformin use and survival of patients with colorectal cancer: A Nationwide cohort study. *Int J Cancer*. 2020 Oct 1;147(7):1904-1916. IF(2023): 5.7, ONCOLOGY|Q1|54/322 (16.7%)

49. Lee CH, Hsieh JC, Wu TM, Yeh TS, Wang HM, Lin YC, Chen JS, Lee CL, Huang WK, Hung TM, Yen TT, Chan SC, Chou WC, Kuan FC, Hu CC, Chang PH. Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer. *BMC Cancer*. 2019 Dec 2;19(1):1167. IF(2023):3.4, ONCOLOGY|Q2|110/322 (34.1%)

50. Chen DY, Huang WK, Chien-Chia Wu V, Chang WC, Chen JS, Chuang CK, Chu PH. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. *J Formos Med Assoc*. 2020 Oct;119(10):1461-1475. IF(2023): 2.6, MEDICINE, GENERAL & INTERNAL|Q1|70/325 (21.5%)

51. Chang PH, Wu MH, Liu SY, Wang HM, Huang WK, Liao CT, Yen TC, Ng SH, Chen JS, Lin

- YC, Lin HC, Hsieh JC. The Prognostic Roles of Pretreatment Circulating Tumor Cells, Circulating Cancer Stem-Like Cells, and Programmed Cell Death-1 Expression on Peripheral Lymphocytes in Patients with Initially Unresectable, Recurrent or Metastatic Head and Neck Cancer: An Exploratory Study of Three Biomarkers in One-time Blood Drawing. *Cancers (Basel)*. 2019 Apr 15;11(4):540. IF(2023):4.5, ONCOLOGY|Q1|78/322 (24%)
52. Hou CH, Lee JS, Lin KK, Chang SH, Huang WK, Kuo CF, See LC. Endophthalmitis Incidence of Cancer Patients After Cataract Surgery: A Nationwide Matched Cohort Study in Taiwan. *Am J Ophthalmol*. 2019 Mar;199:246-254. IF(2023):4.1, OPHTHALMOLOGY|Q1| 10/95 (10.5%)
53. Huang WK, Akçakaya P, Gangaev A, Lee L, Zeljic K, Hajeri P, Berglund E, Ghaderi M, Åhlén J, Bränström R, Larsson C, Lui WO. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors. *Exp Cell Res*. 2018 Oct 1;371(1):287-296. IF(2023):3.3, ONCOLOGY|Q2|118/322 (36.6%)
54. Huang WK, Juang YY, Chung CC, Chang SH, Chang JW, Lin YC, Wang HM, Chang HK, Chen JS, Tsai CS, Yu KH, Kuo CF, See LC. Timing and risk of mood disorders requiring psychotropics in long-term survivors of adult cancers: A nationwide cohort study. *J Affect Disord*. 2018 Aug 15;236:80-87. IF(2023):4.9, PSYCHIATRY|Q1|38/276 (13.7%) IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)
55. Chou WC, Wu MH, Chang PH, Hsu HC, Chang GJ, Huang WK, Wu CE, Hsieh JC. A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer. *Int J Biol Sci*. 2018 Jan 12;14(2):137-146. IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)
56. Kao WH, Kuo CF, Chou IJ, See LC, Huang WK, Chiou MJ, Zhang W, Doherty M, Wang CC, Hsu JT, Chen HH, Hong JH. Prostate-selective α antagonists increase fracture risk in prostate cancer patients with and without a history of androgen deprivation therapy: a nationwide population-based study. *Oncotarget*. 2018 Jan 2;9(4):5263-5273.
57. Chen DY, See LC, Liu JR, Chuang CK, Pang ST, Hsieh IC, Wen MS, Chen TH, Lin YC, Liaw CC, Hsu CL, Chang JW, Kuo CF, Huang WK*. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study. *J Clin Oncol*. 2017 Nov 10;35(32):3697-3705. IF(2023): 42.1, ONCOLOGY|Q1|6/322 (1.8%)
58. Su PJ, Wu MH, Wang HM, Lee CL, Huang WK, Wu CE, Chang HK, Chao YK, Tseng CK, Chiu TK, Lin NM, Ye SR, Lee JY, Hsieh CH. Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy. *Sci Rep*. 2016 Aug 17;6:31423.
59. Huang WK, Kuo TT, Wu CE, Cheng HY, Hsieh CH, Hsieh JJ, Shen YC, Hou MM, Hsu T, Chang JW. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan. *Asia Pac J Clin Oncol*. 2016 Dec;12(4):403-408.
60. Yu KH, Kuo CF, Huang LH, Huang WK, See LC. Cancer Risk in Patients With Inflammatory

Systemic Autoimmune Rheumatic Diseases: A Nationwide Population-Based Dynamic Cohort Study in Taiwan. *Medicine (Baltimore)*. 2016 May;95(18):e3540.

61. **Huang WK**, Hsu HC, Liu JR, Yang TS, Chen JS, Chang JW, Lin YC, Yu KH, Kuo CF, See LC. The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk: A Nationwide Cohort Study. *Medicine (Baltimore)*. 2016 Mar;95(11):e2980.

62. Huang CY, Lu CH, Yang CK, Hsu HC, Kuo YC, **Huang WK**, Chen JS, Lin YC, Chia-Yen H, Shen WC, Chang PH, Yeh KY, Hung YS, Chou WC. A Simple Risk Model to Predict Survival in Patients With Carcinoma of Unknown Primary Origin. *Medicine (Baltimore)*. 2015 Nov;94(47):e2135.

63. **Huang WK**, Tu HT, See LC. Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence. *Curr Pharm Des*. 2015;21(35):5108-15.

64. Wu CF, Wang HM, **Huang WK**, Chang JW. Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma. *Asia Pac J Clin Oncol*. 2015 Dec;11(4):314-8.

68. Lin CY, **Huang WK**, Chung FT, Chang HK. Prognostic factors in cancer patients with symptomatic pituitary metastasis: a clinical case study. *Anticancer Res*. 2015 Feb;35(2):983-7.

69. Wu CE, Wang CW, **Huang WK**, Yang CT, Wu YC, Hou MM, Hsieh CH, Hsieh JJ, Cheng HY, Hsu T, Chang JW. Cytoplasmic and nuclear parathyroid hormone-related proteins are opposing prognostic factors in patients with non-small-cell lung cancer who have undergone curative resection. *Jpn J Clin Oncol*. 2015 Mar;45(3):267-73.

70. **Huang WK**, Kuo YC, Tsang NM, Hsu HC, Shen WC, Chou WC, Yang TS, Chen JS. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer. *Anticancer Res*. 2014 Nov;34(11):6755-61.

71. **Huang WK**, Chiou MJ, Kuo CF, Lin YC, Yu KH, See LC. No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan. *Rheumatol Int*. 2014 Oct;34(10):1379-86.

72. **Huang WK**, Lin YC, Chiou MJ, Yang TS, Chang JW, Yu KH, Kuo CF, See LC. Pyogenic liver abscess as a warning sign for primary liver cancer: a nationwide population-based study. *Asian Pac J Cancer Prev*. 2013;14(8):4727-31.

73. **Huang WK**, Chiou MJ, Yu KH, Lin YC, Yang TS, Chen JS, Kuo CF, See LC. The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study. *Aliment Pharmacol Ther*. 2013 Aug;38(4):432-9.

74. **Huang WK**, Liaw CC, Pang ST, Chuang CK, Chiang YJ, Wu CT, Chang YH, Wang HM, Lin YC, Hsieh JJ, Ou LY, Tsai SI, Yang CH, Yang CT, Chang JW. Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital. *Chang Gung Med J*. 2012 Sep-Oct;35(5):402-7.

75. **Huang WK**, Chang JW, See LC, Tu HT, Chen JS, Liaw CC, Lin YC, Yang TS. Higher rate of colorectal cancer among patients with pyogenic liver abscess with *Klebsiella pneumoniae* than those without: an 11-year follow-up study. *Colorectal Dis*. 2012 Dec;14(12):e794-801.